SCHEMBL498003

SCHEMBL498003

C#Cc1ccccc1C(=O)OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.55
LMNA P02545 2/20 0.55
ALDH1A1 P00352 4/20 0.53
HSD17B10 Q99714 4/20 0.53
CFTR P13569 1/20 0.53
KDM4E B2RXH2 5/20 0.52
POLB P06746 2/20 0.52
ATM Q13315 1/20 0.52
KMT2A Q03164 2/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA5A P35218 1/20 0.47
CA9 Q16790 1/20 0.47
MAPT P10636 1/20 0.47
ALOX15 P16050 1/20 0.47
SLC6A3 Q01959 4/20 0.46
MYC P01106 1/20 0.46
SLC6A4 P31645 2/20 0.45
GLA P06280 1/20 0.45
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15611971 0.95 SLC6A3 (0.51) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL1926587 0.90 LMNA (0.46) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL70467 0.84 TSHR (0.59) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL25044297 0.84 LMNA (0.46) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL9108150 0.84 CA1 (0.48) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL380146 0.82 TSHR (0.57) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL16719456 0.82 TSHR (0.44) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL29628477 0.82 PDK1 (0.45) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL24626055 0.82 TSHR (0.44) TSHRLMNAALDH1A1HSD17B10CFTR
Benzene SCHEMBL28861660 0.82 LMNA (0.44) TSHRLMNAALDH1A1HSD17B10CFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3647315-B9 PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF VIVAVISION BIOTECH LTD (CN) 2025-06-04 EP claimed
EP-3647315-B1 PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF VIVAVISION BIOTECH LTD (CN) 2024-11-20 EP claimed
US-11325929-B2 Phosphorus-containing compound and preparation and use thereof VIVAVISIONSHANGHAILTD (CN) 2022-05-10 US claimed
EP-3647315-A1 PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF Vivavisionshanghailtd (CN) 2020-05-06 EP claimed
US-20200131206-A1 PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF VIVAVISIONSHANGHAILTD (CN) 2020-04-30 US claimed
EP-3051946-B1 USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES OR THEIR SALTS FOR INCREASING STRESS TOLERANCE IN PLANTS BAYER CROPSCIENCE AG (DE) 2017-11-29 EP claimed
US-12577242-B2 Pyrrolopyridine and imidazopyridine antiviral compounds KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2026-03-17 US disclosed
EP-3647315-B9 PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF VIVAVISION BIOTECH LTD (CN) 2025-06-04 EP disclosed
EP-3647315-B1 PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF VIVAVISION BIOTECH LTD (CN) 2024-11-20 EP disclosed
US-20240132431-A1 METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-04-25 US disclosed
US-20240043439-A1 COMPOUNDS AS C5AR INHIBITORS KIRA PHARMACEUTICALS (SUZHOU) LTD. (CN) 2024-02-08 US disclosed
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2024-01-25 US disclosed
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2024-01-25 US disclosed
WO-2005116198-A2 METHODS OF 1,3-ENYNE PREPARATION USING COPPER (I) CATALYSTS UNIVERSITY OF MASSACHUSETTS (US) 2005-12-08 WO disclosed
US-20050255575-A1 Methods of 1,3-enyne preparation using copper (I) catalysts NATIONAL SCIENCE FOUNDATION 2005-11-17 US disclosed
US-20050090669-A1 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists ASTELLAS PHARMA INC. (JP) 2005-04-28 US disclosed
EP-1483236-A1 AMINOALCOHOL DERIVATIVES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-08 EP disclosed
WO-2003076397-A1 AMINOALCOHOL DERIVATIVES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 WO disclosed
EP-0834499-B1 Process for the preparation of aromatic vinyl compounds DAINIPPON INK & CHEMICALS (JP) 2001-07-25 EP disclosed
EP-0834499-A1 Process for the preparation of aromatic vinyl compounds DAINIPPON INK AND CHEMICALS, INC. (JP) 1998-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577242-B2 Pyrrolopyridine and imidazopyridine antiviral compounds SARS1, TPMT, ZC3HAV1 TSHR 1599/4885LMNA 2248/4885ALDH1A1 3438/4885
US-11325929-B2 Phosphorus-containing compound and preparation and use thereof INPP5D, CXCL12, INPPL1 TSHR 2839/4885LMNA 4656/4885ALDH1A1 4021/4885
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS TSHR 2610/4885LMNA 4706/4885ALDH1A1 4316/4885
US-20240043439-A1 COMPOUNDS AS C5AR INHIBITORS C5AR1, C5AR2, C3AR1 TSHR 565/4885LMNA 2579/4885ALDH1A1 3678/4885
US-20240132431-A1 METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP MGMT, MCL1, FANCF TSHR 3360/4885LMNA 2336/4885ALDH1A1 446/4885
US-20200131206-A1 PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF INPP5D, CXCL12, INPPL1 TSHR 2839/4885LMNA 4656/4885ALDH1A1 4021/4885
US-20050090669-A1 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists ADRB2, ADRB1, ADRB3 TSHR 1056/4885LMNA 2444/4885ALDH1A1 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.